8-K: 10x Genomics Appoints Sarah A. Teichmann to Board of Directors
Director Appointment
10x Genomics has appointed Dr. Sarah A. Teichmann, a prominent figure in genomics and computational biology, to its Board of Directors, effective immediately.
Summary
- 10x Genomics has appointed Sarah A. Teichmann to its Board of Directors as a Class II director.
- Her term will expire at the company's 2027 annual meeting of stockholders.
- Dr. Teichmann is a distinguished academic with extensive experience in genomics, computational biology, and leadership roles at various research institutions.
- She currently serves as Chair in Stem Cell Medicine at the University of Cambridge and Vice President at Glaxo Smith Kline.
- She is also a co-founder of the Human Cell Atlas initiative.
- Dr. Teichmann will receive an annual cash retainer of $55,000.
- She will also receive a one-time grant of restricted stock units valued at $400,000, vesting over three years.
- Additionally, she will receive an annual grant of restricted stock units valued at $215,000, vesting quarterly.
- Dr. Teichmann has entered into the company's standard indemnification agreement.
Sentiment
Score: 8
Explanation: The appointment of a highly qualified individual to the board is a positive development for the company. The compensation package is standard and the overall tone is optimistic.
Positives
- The appointment of Dr. Teichmann brings significant expertise in genomics and computational biology to the board.
- Her extensive leadership experience at prominent research institutions is a valuable asset.
- The compensation package is structured to align her interests with the company's long-term success.
- Her involvement with the Human Cell Atlas initiative could provide valuable insights and connections.
Risks
- There are no immediate risks associated with this appointment.
- The vesting schedule of the stock grants could potentially impact her long-term commitment.
Future Outlook
The company expects Dr. Teichmann to contribute significantly to the board due to her extensive experience and expertise.
Management Comments
- The Company believes Dr. Teichmann is qualified to serve on the Board of Directors because of her extensive academic training, significant contributions to the field of genomics and her many years of experience in leadership roles at prominent research institutions.
Industry Context
The appointment of a prominent figure in genomics aligns with the industry's focus on innovation and scientific leadership. This move could enhance 10x Genomics' reputation and attract further talent.
Comparison to Industry Standards
- The compensation package for Dr. Teichmann is in line with industry standards for non-employee directors at similar biotech companies.
- Companies like Illumina and Pacific Biosciences also attract top scientific talent to their boards with similar compensation structures.
- The appointment of a co-founder of the Human Cell Atlas is a significant move, similar to how other companies have brought in leaders from major research initiatives.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | NA | Sarah A. Teichmann | July 10, 2024 | Appointment to the Board of Directors |
Stakeholder Impact
- Shareholders may view this appointment positively, as it brings valuable expertise to the board.
- Employees may be encouraged by the company's ability to attract top talent.
- Customers and partners may see this as a sign of the company's commitment to innovation.
Next Steps
- Dr. Teichmann will begin her service on the Board of Directors immediately.
- The one-time grant of restricted stock units will be granted on August 30, 2024.
- The annual grant of restricted stock units will be granted at the next annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| September 3, 2019 | Filing date of the Companys Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-233361) which contains the standard indemnification agreement. |
| October 2016 | Dr. Teichmann co-founded the Human Cell Atlas (HCA) and became co-chair of the HCA Organizing Committee. |
| April 2020 | Dr. Teichmann became co-chair of the board of directors of Human Cell Atlas, Inc. |
| September 2023 | Dr. Teichmann became a co-founder, consultant, Chief Scientific Officer and board member of EnsoCell Therapeutics. |
| January 2024 | Dr. Teichmann became Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline plc. |
| April 2024 | Dr. Teichmann became Chair in Stem Cell Medicine at the University of Cambridge. |
| July 10, 2024 | Date of appointment of Sarah A. Teichmann to the Board of Directors of 10x Genomics. |
| August 30, 2024 | Date of the one-time grant of restricted stock units to Dr. Teichmann. |
| November 21, 2025 | First vesting date for one third of the one-time grant of restricted stock units. |
| 2027 | Expected year of expiration of Dr. Teichmann's term on the Board of Directors. |
Keywords
Board of Directors, Genomics, Sarah A. Teichmann, Computational Biology, Stock Options, Corporate Governance, Executive Appointment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.